Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer

por Terwogt, J M M, Mandjes, I A M, Sindermann, H, Beijnen, J H, ten Bokkel Huinink, W W
Publicado 1999

Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response

por Lips, E. H., Mulder, L., de Ronde , J. J., Mandjes, I. A. M., Koolen, B. B., Wessels, L. F. A., Rodenhuis, S., Wesseling, J.
Publicado 2013

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.

por Herben, V. M., ten Bokkel Huinink, W. W., Dubbelman, A. C., Mandjes, I. A., Groot, Y., van Gortel-van Zomeren, D. M., Beijnen, J. H.
Publicado 1997

Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer

por Rigter, L S, Loo, C E, Linn, S C, Sonke, G S, van Werkhoven, E, Lips, E H, Warnars, H A, Doll, P K, Bruining, A, Mandjes, I A, Vrancken Peeters, M J, Wesseling, J, Gilhuijs, K G, Rodenhuis, S
Publicado 2013

Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial

por Geurts, V.C.M., Voorwerk, L., Balduzzi, S., Salgado, R., Van de Vijver, K., van Dongen, M.G.J., Kemper, I., Mandjes, I.A.M., Heuver, M., Sparreboom, W., Haanen, J.B.A.G., Sonke, G.S., Horlings, H.M., Kok, M.
Publicado 2023